$CNBX
CNBX Pharmaceuticals Inc

2024 Q2 Form 10-Q Financial Statement

#000168316824002440 Filed on April 16, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $0.00 $40.64K $0.00
YoY Change -100.0%
Cost Of Revenue $6.220K $0.00
YoY Change
Gross Profit $34.42K $0.00
YoY Change
Gross Profit Margin 84.69%
Selling, General & Admin $109.4K $133.7K $237.7K
YoY Change -50.31% -43.77% -40.53%
% of Gross Profit 388.29%
Research & Development $42.88K $107.2K $12.33K
YoY Change -83.7% 769.57% -96.27%
% of Gross Profit 311.45%
Depreciation & Amortization $0.00 $32.86K $40.39K
YoY Change -100.0% -18.64% -20.16%
% of Gross Profit 95.47%
Operating Expenses $152.3K $240.9K $250.0K
YoY Change -68.49% -3.66% -65.76%
Operating Profit -$152.3K -$206.4K -$250.0K
YoY Change -12.02% -17.43% -65.76%
Interest Expense $21.65K -$119.0K -$2.374M
YoY Change 17.73% -94.99% 366.82%
% of Operating Profit
Other Income/Expense, Net $21.65K $4.680K $20.99K
YoY Change 17.69% -77.7% -104.13%
Pretax Income -$130.6K -$325.5K -$2.624M
YoY Change -15.55% -87.6% 111.83%
Income Tax
% Of Pretax Income
Net Earnings -$130.6K -$325.5K -$2.624M
YoY Change -15.55% -87.6% 111.83%
Net Earnings / Revenue -800.84%
Basic Earnings Per Share $0.00 -$0.01 -$1.33
Diluted Earnings Per Share $0.00 -$0.01 -$1.33
COMMON SHARES
Basic Shares Outstanding 31.11M shares 31.11M shares 1.258M shares
Diluted Shares Outstanding 31.11M shares 30.99M shares 1.963M shares

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $73.41K $37.14K $47.75K
YoY Change 66.27% -22.22% -79.39%
Cash & Equivalents $73.41K $37.14K $47.75K
Short-Term Investments
Other Short-Term Assets $6.620K $126.8K $61.09K
YoY Change -97.83% 107.53% -63.63%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $80.03K $163.9K $108.8K
YoY Change -77.06% 50.61% -72.76%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00 $353.2K
YoY Change -100.0% -100.0% -34.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change -100.0%
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $353.2K
YoY Change -100.0% -100.0% -52.15%
TOTAL ASSETS
Total Short-Term Assets $80.03K $163.9K $108.8K
Total Long-Term Assets $0.00 $0.00 $353.2K
Total Assets $80.03K $163.9K $462.1K
YoY Change -87.91% -64.52% -59.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $189.8K $231.4K $710.6K
YoY Change -81.3% -67.44% 199.57%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $1.294M $1.293M $1.539M
YoY Change -2.91% -16.03% 16.18%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.534M $2.522M $2.474M
YoY Change -1.44% 1.98% 38.51%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.534M $2.522M $2.474M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.534M $2.522M $2.474M
YoY Change -1.44% 1.98% 38.51%
SHAREHOLDERS EQUITY
Retained Earnings -$24.89M -$24.76M -$23.53M
YoY Change 5.1% 5.24%
Common Stock $3.111K $3.111K $222.00
YoY Change 94.07% 1301.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.454M -$2.359M -$2.012M
YoY Change
Total Liabilities & Shareholders Equity $80.03K $163.9K $462.1K
YoY Change -87.91% -64.52% -59.39%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$130.6K -$325.5K -$2.624M
YoY Change -15.55% -87.6% 111.83%
Depreciation, Depletion And Amortization $0.00 $32.86K $40.39K
YoY Change -100.0% -18.64% -20.16%
Cash From Operating Activities $220.00 -$124.4K -$18.53K
YoY Change -101.18% 571.29% -96.66%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $94.67K $20.00K $24.70K
YoY Change -19.03%
Cash From Investing Activities $94.68K $20.00K $24.70K
YoY Change -19.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.260K 0.000 19.98K
YoY Change -91.59% -100.0%
NET CHANGE
Cash From Operating Activities 220.0 -124.4K -18.53K
Cash From Investing Activities 94.68K 20.00K 24.70K
Cash From Financing Activities 1.260K 0.000 19.98K
Net Change In Cash 96.16K -104.4K 26.15K
YoY Change -2771.11% -499.2% -104.71%
FREE CASH FLOW
Cash From Operating Activities $220.00 -$124.4K -$18.53K
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow $220.00 -$124.4K -$18.53K
YoY Change -101.18% 571.29% -96.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--08-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
6220 usd
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
us-gaap Cost Of Revenue
CostOfRevenue
17570 usd
us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2024Q1 us-gaap Gross Profit
GrossProfit
34417 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
0 usd
us-gaap Gross Profit
GrossProfit
112504 usd
us-gaap Gross Profit
GrossProfit
0 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
107199 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12328 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
208267 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
75215 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
133646 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
237683 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
282565 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
521585 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
240845 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
250010 usd
us-gaap Operating Expenses
OperatingExpenses
490832 usd
us-gaap Operating Expenses
OperatingExpenses
596800 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-206428 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-250010 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-378328 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-596800 usd
CY2024Q1 CNBX Capital Loss
CapitalLoss
-123711 usd
CY2023Q1 CNBX Capital Loss
CapitalLoss
-2395298 usd
CNBX Capital Loss
CapitalLoss
-123711 usd
CNBX Capital Loss
CapitalLoss
-2395298 usd
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4680 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
20987 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1943 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10108 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-325459 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2624321 usd
us-gaap Net Income Loss
NetIncomeLoss
-503982 usd
us-gaap Net Income Loss
NetIncomeLoss
-2981990 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-59870 usd
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-325459 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2624321 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-503982 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3041860 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.33
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.42
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30988275 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30988275 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1962999 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1962999 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29374538 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29374538 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2086873 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2086873 shares
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-2017289 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
69950 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
92787 usd
us-gaap Net Income Loss
NetIncomeLoss
-503982 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-2358534 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2094929 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34975 usd
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
26879 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-325459 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-2358534 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1632311 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
110530 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
248326 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2243913 usd
us-gaap Net Income Loss
NetIncomeLoss
-2981990 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-2011532 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1974293 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34973 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
248327 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2303783 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2624321 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-2011532 usd
us-gaap Net Income Loss
NetIncomeLoss
-503982 usd
us-gaap Net Income Loss
NetIncomeLoss
-2981990 usd
us-gaap Depreciation
Depreciation
72320 usd
us-gaap Depreciation
Depreciation
83575 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
16798 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
9034 usd
CNBX Capital Loss1
CapitalLoss1
-123711 usd
CNBX Capital Loss1
CapitalLoss1
-2395298 usd
us-gaap Share Based Compensation
ShareBasedCompensation
69950 usd
us-gaap Share Based Compensation
ShareBasedCompensation
110530 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
32163 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-19685 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
57122 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
249421 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-196244 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-114447 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
24702 usd
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
1196 usd
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
-0 usd
us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
20000 usd
us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
18804 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
24702 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
24993 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
19978 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24993 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19978 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
59893 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-92554 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-69767 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
129696 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
117515 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37142 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47748 usd
us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
20000 usd
CNBX Capital Loss
CapitalLoss
-123711 usd
us-gaap Net Income Loss
NetIncomeLoss
-503982 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24763184 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
208267 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
75215 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_84E_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zqHmePCdUUxa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reclassifications</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses, total assets, or stockholders’ equity as previously reported.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
us-gaap Share Based Compensation
ShareBasedCompensation
69950 usd
us-gaap Share Based Compensation
ShareBasedCompensation
110530 usd
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q1 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
8500000 shares
CY2024Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
92787 usd
CNBX Monthly Operating Lease Expense
MonthlyOperatingLeaseExpense
6500 usd
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001683168-24-002440-index-headers.html Edgar Link pending
0001683168-24-002440-index.html Edgar Link pending
0001683168-24-002440.txt Edgar Link pending
0001683168-24-002440-xbrl.zip Edgar Link pending
cnbx-20240229.xsd Edgar Link pending
cnbx_ex3101.htm Edgar Link pending
cnbx-20240229_cal.xml Edgar Link unprocessable
cnbx-20240229_def.xml Edgar Link unprocessable
cnbx-20240229_lab.xml Edgar Link unprocessable
cnbx-20240229_pre.xml Edgar Link unprocessable
cnbx_ex3102.htm Edgar Link pending
cnbx_ex3201.htm Edgar Link pending
cnbx_ex3202.htm Edgar Link pending
cnbx_i10q-022924.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
image_002.jpg Edgar Link pending
image_003.jpg Edgar Link pending
image_004.jpg Edgar Link pending
image_005.jpg Edgar Link pending
image_006.jpg Edgar Link pending
image_007.jpg Edgar Link pending
image_008.jpg Edgar Link pending
image_009.jpg Edgar Link pending
image_010.jpg Edgar Link pending
image_011.jpg Edgar Link pending
image_012.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cnbx_i10q-022924_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable